Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldara AK Monitoring Pilot
NCT00294320Phase 3Completed
- Sponsor
- Meda
- Start
- Feb 2006
- Primary completion
- Jan 2007
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in actinic keratosis (AK) comparing Aldara (Imiquimod) with Vehicle cream (2 arms). Primary endpoint: Performance of two techniques to monitor the clearance of AK lesions (clinical and subclinical) by comparison of lesion counts. Started Feb 2006; status: completed.
02
Drugs
imiquimod
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00294320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00294320.